Brought to you by 
Merck & Co. acquires remaining 49% of Banyu
10 Dec 2007
Executive Summary
Merck & Co., through its Merck Sharp & Dohme Japanese subsidiary, will acquire the remaining 49% of Banyu Pharmaceutical that it does not already own (about 130mm shares) for $1.5bn (Yen180.9bn).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck & Co. acquires remaining 49% of Banyu
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice